Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057693 · ClinicalTrials.gov registry record · Phase 3
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 633
- Enrollment target
NCT01057693 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 633 participants.
The verdict
NCT01057693, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 633 participants
- Enrollment target
Study Summary
Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.
Interventions
- DRUG Placebo
- DRUG pregabalin (Lyrica)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 633 participants |
| Start Date | 2010-03-31 |
| Est. Completion | 2012-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057693
The ClinicalTrials.gov registry entry for NCT01057693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 633 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01057693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057693 about?
NCT01057693 is a clinical study titled "Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy". Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.
What is the current status of trial NCT01057693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 633 participants. The study started on 2010-03-31. Estimated completion is 2012-01-30.
What interventions are being tested in trial NCT01057693?
The interventions under investigation include: Placebo (DRUG), pregabalin (Lyrica) (DRUG).
Who is sponsoring clinical trial NCT01057693?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.